Syndax Pharmaceuticals Inc Stock News

WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on…

Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call Transcript

The clinical-stage biotech, Syndax Pharmaceuticals (SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer,…

Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of $1.81 beats by $1.84.Revenue of $126.6M (+63200.0% Y/Y) beats by $67.92M.

WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended…

Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is $0.46 (+204.5% Y/Y) and…

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and

During the last session, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)s traded shares were 0.55 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stocks price was $16.44, reflecting an intraday gain of 3.98% or $0.63. The 52-week high for the SNDX share is $25.68, that puts it down Is Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Still A Buy After A 9.75% Weekly Jump? Read More »

Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-ago quarter. The stoc

Syndax Pharmaceuticals (SNDX) said Michael Metzger, president and COO, will transition to the role of CEO, effective Feb

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Alla

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos''s Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Allakos, Inc. (NASDAQ: ALLK ) announced data from ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis and KRYPTOS Phase 2/3 study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. The stock was down 7.69% to $77.90 in premarket trading. FDA Imposes Clinical Hold On Injectable Form Of Gilead''s HIV Drug Candidate Due to Concerns Over Vial Quality Gilead Sciences, Inc. (NASDAQ: GILD ) announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.

Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []

Related Stocks: SNDX ,

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned an average recommendation of Buy from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered []